Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.63 |
| ▸ | FPR2 | P25090 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.54 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | ALB | P02768 | 1/20 | 0.52 |
| ▸ | IL2 | P60568 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.52 |
| ▸ | ITGAV | P06756 | 1/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10663117 | 1.00 | LDHA (0.63) | LDHAFPR2KMT2ACA2ITGA4 | |
| SCHEMBL7430458 | 0.88 | FPR2 (0.57) | LDHAFPR2KMT2ACA2ALDH1A1 | |
| SCHEMBL6437450 | 0.88 | FPR2 (0.57) | LDHAFPR2KMT2ACA2ALDH1A1 | |
| SCHEMBL6437447 | 0.88 | FPR2 (0.57) | LDHAFPR2KMT2ACA2ALDH1A1 | |
| SCHEMBL16879017 | 0.88 | LDHA (0.54) | LDHAFPR2KMT2AALDH1A1 | |
| SCHEMBL4361126 | 0.88 | ITGB3 (0.64) | LDHAFPR2KMT2ACA2ALDH1A1 | |
| SCHEMBL10660397 | 0.88 | ITGB3 (0.64) | LDHAFPR2KMT2ACA2ALDH1A1 | |
| SCHEMBL16879018 | 0.88 | LDHA (0.54) | LDHAFPR2KMT2AALDH1A1 | |
| SCHEMBL6438360 | 0.88 | ITGB3 (0.64) | LDHAFPR2KMT2ACA2ALDH1A1 | |
| SCHEMBL1308867 | 0.87 | ITGB3 (0.67) | LDHAFPR2KMT2ACA2ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696639-B2 | Heterocyclic compounds as HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696639-B2 | Heterocyclic compounds as HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190337902-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-11-07 | — | — | US | disclosed |
| US-20190337902-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-11-07 | — | — | US | disclosed |
| EP-3551192-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2019-10-16 | — | — | EP | disclosed |
| WO-2018106519-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106519-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-06-14 | — | — | WO | disclosed |
| CN-1063430-C | Ethanolamine derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-03-21 | — | — | CN | disclosed |
| EP-0583485-B1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-08-13 | — | — | EP | disclosed |
| US-5387710-A | Ethanolamine derivatives having sympathomimetic and anti-pollakiuria activities | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-07 | — | — | US | disclosed |
| CN-1084846-A | Ethanolamine derivant | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-04-06 | — | — | CN | disclosed |
| EP-0583485-A1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES. | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-02-23 | — | — | EP | disclosed |
| WO-1993015041-A1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-05 | — | — | WO | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696639-B2 | Heterocyclic compounds as HIV protease inhibitors | PREP, SERPINB1, PEPD | LDHA 1989/4885FPR2 1455/4885KMT2A 2200/4885 |
| US-20190337902-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | PREP, SERPINB1, PEPD | LDHA 1989/4885FPR2 1455/4885KMT2A 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.